FDA Decision On CBD Use Could Run Up Against Chicken Or Egg Question
Speakers at FDA's first-ever public hearing on using cannabis-derived ingredients in products subject to its oversight asked agency officials to look back further than history of drug research with cannabinoids to earlier than the origin of its regulations as it considers its decision. "CBD is a constituent inherent in hemp which has been marketed and used at least since the Civil War," says cannabis business attorney Rob Kight.
You may also be interested in...
FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.
US cannabis research funding of $189m, growing 65% since 2016, isn’t keeping pace with demand for CBD products with sales projected to surpass $20bn by 2024, says the Collaborative for CBD Science and Safety. It urges industry to accelerate R&D and FDA to move forward with a regulatory framework.
US Wellness Market In 2019: Farm Bill Made Cultivating Cannabidiol Policy FDA's Main Course In Supplements
As HBW Insight looks back on notable US wellness market developments and events for the previous 12 months, we find that news in the CBD space from the FDA and the industry dominated the sector throughout 2019.